Abstract:Real-world evidence (RWE) has an increasing role in preapproval settings to support the approval of new medicines and indications. The main objectives of this study were to identify and characterize regulatory use cases that utilized RWE and other related observational approaches through targeted review of publications and regulatory review documents. After screening and inclusion/exclusion, the review characterized 85 regulatory applications with RWE. A total of 31 were in oncology and 54 were in non-oncology therapeutic areas. Most were for indications in adults only (N = 42, 49.4%), while 13 were in pediatrics only (15.3%), and 30 were in both (35.3%). In terms of regulatory context, 59 cases (69.4%) were for an original marketing application, 24 (28.2%) were for label expansion, and 2 (2.4%) were for label modification. Most also received special regulatory designations (e.g., orphan indication, breakthrough therapy, fast track, conditional, and accelerated approvals). There were 42 cases that utilized RWE to support single-arm trials. External data to support single-arm trials were utilized in various ways across use cases, including direct matching, benchmarking, natural history studies as well as literature or previous trials. A variety of data sources were utilized, including electronic health records, claims, registries, site-based charts. Endpoints in oncology use cases commonly included overall survival, progression-free survival. In 13 use cases, RWE was not considered supportive/definitive in regulatory decision-making due to design issues (e.g., small sample size, selection bias, missing data). Overall, RWE is utilized in regulatory approval processes for new indications/label expansion across various therapeutic areas with wide range of approaches. Multifaceted cross-sector efforts are needed to further improve the quality and utility of RWE in regulatory decision-making.

Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions

The Use of Real‐World Evidence for Regulatory Decisions in China

Drug Review and Approval Policies Based on Real-world Evidence in China and the United States: A Comparative Study

Use of Real-World Evidence in Regulatory Decisions for Traditional Chinese Medicine: Current Status and Future Directions

Use of Real-World Evidence to Support Regulatory Decisions on Medical Devices in China and a Unique Opportunity to Gain Accelerated Approval in "boao Lecheng Pilot Zone".

Establishment of RWS guidance reflecting contributions of China to regulatory science

The Use of Real-World Data/evidence in Regulatory Submissions.

On the use of RWD in support of regulatory submission in drug development

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Utilization of real-world evidence in clinical research of medical devices

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases

Advancing the development of real-world data for healthcare research in China: challenges and opportunities

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.

Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment

Use of real world data to improve drug coverage decisions in China

Real-World Evidence: A Primer

Expert survey on real‐world data utilization and real‐world evidence generation for regulatory decision‐making in drug lifecycle in Korea